As a method of identifying novel therapeutic targets in this disease subtype, we utilize a microRNA that reverses the Epithelial-to-Mesenchymal Transition, which reveals Niemann-Pick C1 (NPC1) as a gene highly expressed in triple negative breast cancer. The gene discussed is NPC1; the disease is triple-negative breast carcinoma.